This week saw the publication of The Sunday Times Profit Track 100, and we are delighted to announce that Randox has been named at number 65 in the league table which ranks the 100 private UK companies with the fastest-growing profits over a three-year period.

Stuart Lisle, of BDO Accountants, featured Randox in his piece; ‘Innovation and trade make a good formula for expansion’, noting impressive findings that:

• Randox supplies 10% of the world’s cholesterol tests
• Our diagnostic products are used in 145 countries across the globe

Stuart Lisle commented;

“After outperforming most of our peers, Britain is entering a period of economic uncertainty: stock markets are volatile, growth in China is slowing, Europe’s recovery has stalled and, as the Bank of England governor Mark Carney noted in March, the possibility of Brexit is not helping.  Our polling shows that 70% of mid-market companies think leaving the EU would make running their businesses harder but there are strong arguments on both sides of the debate.

Thankfully, while our politicians talk in Westminster, our mid-market companies are getting on with business, driving growth by innovating at home and trading overseas.

This year’s Profit Track 100 contains numerous examples.  Just look at what Peter FitzGerald, founder of Randox Laboratories is achieving.  From humble beginnings in his parents’ garden shed in County Antrim, Northern Ireland, he has developed the firm into one the supplies 10% of the world’s cholesterol tests as well as a range of other diagnostic instruments used in 145 countries…and it is one of 55 companies in this year’s Profit Track 100 that are growing by selling internationally.”

We would like to thank Stuart for recognising our success and innovation.  We are extremely proud of how far the company has come – from humble beginnings over 34 years ago, to a company with more than 1400 employees of 44 nationalities, including 300 research scientists and engineers.

Dr Peter FitzGerald, Managing Director of Randox said:

“The growth that we have witnessed over the last 3 years principally enables us to further strengthen our infrastructure and increase the world leading research and development we are conducting – to achieve the earliest possible diagnosis of a very wide range of clinical conditions. We remain dedicated to saving lives and improving health worldwide, and reinvesting our profits helps ensure that we will realise our vision.”

The Profit Track 100 league table is compiled by Fast Track, the Oxford-based research and networking events firm.